This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top
by Zacks Equity Research
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
Vertex Pharmaceuticals (VRTX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -2.22% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
by Zacks Equity Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.
Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies
by Zacks Equity Research
Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market.
TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View
by Zacks Equity Research
TEVA reports in-line Q1 earnings but misses estimates for sales. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Should You Buy Vertex (VRTX) Ahead of Earnings?
by Zacks Equity Research
Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
by Nalak Das
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.
Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig
by Zacks Equity Research
Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Axsome (AXSM) reports a slightly wider-than-estimated Q1 loss. It expects to receive FDA approval for its lead candidate AXS-05 by second-quarter 2022 to treat major depressive disorder.
What Awaits Meridian Bioscience (VIVO) This Earnings Season?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal second-quarter results are likely to reflect continued strength across both its segments.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.